BAL modifications after antiblastic and immunomodulant therapy in lung cancer.
The bronchoalveolar compartment can be easily investigated with BAL (bronchoalveolar lavage) before and after antiblastic therapy. We studied 50 patients affected by primary lung cancer, of whom 31 served as a control group and 19 were submitted to BAL after chemo- and/or radiotherapy. Data from BAL performed in an unaffected lung area show that antiblastic therapy can produce alterations in the terminal airways without clinical evidence. Chemotherapy causes a significant impairment of the alveolo-capillary barrier. Radiotherapy is able to affect lymphocytes, with a CD4/CD8 reduction. The concomitance of both therapies produces synergistic effects. Immunomodulant therapy with thymostimulin in otherwise untreated lung cancer patients seems able to modify alveolar lymphocyte number and subsets, but these are preliminary data which need further substantiation.
Capelli
O
O
Department of Physiology and Pulmonary Diseases, University of Modena, Italy.
Rovatti
E
E
Gilioli
F
F
Garuti
G C
GC
Lega
M
M
De Maria
D
D
Covi
M
M
Capitolo
S
S
Fontana
A
A
Pellegrino
M
M
D001992:Bronchoalveolar Lavage Fluid / Q000166:cytology*; D016516:CD4-CD8 Ratio; D003131:Combined Modality Therapy; D006801:Humans; D007958:Leukocyte Count; D008175:Lung Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000532:radiotherapy / Q000628:therapy*; D008214:Lymphocytes / Q000276:immunology; D013949:Thymus Extracts / Q000627:therapeutic use*
D013949:Thymus Extracts; C031407:thymostimulin